Developing new enzymes to create important drug compounds.
A Chemo-Mimetic Platform to Reprogram Metalloenzymes for Non-Natural Biocatalytic C-H Functionalization Reactions
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-10895403
This study is working on improving special proteins called enzymes to help create new medicines more easily, which could lead to better treatments for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10895403 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the capabilities of enzymes to perform specific chemical reactions that are crucial for drug development. By reprogramming metalloenzymes, the team aims to enable these enzymes to catalyze reactions that are not typically found in nature, allowing for the creation of new and complex drug molecules. The approach combines advanced techniques in protein engineering, computational modeling, and organic synthesis to design and test these novel biocatalysts. Patients may benefit from the resulting drugs that could be developed more efficiently and effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that could be treated by new drug compounds developed through enhanced enzymatic processes.
Not a fit: Patients with conditions that are not addressed by the types of drugs being developed in this research may not receive any benefit.
Why it matters
Potential benefit: If successful, this research could lead to the development of new drugs that are more effective and have fewer side effects.
How similar studies have performed: Other research has shown success in using engineered enzymes for drug development, indicating that this approach has potential for significant advancements.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUANG, XIONGYI — JOHNS HOPKINS UNIVERSITY
- Study coordinator: HUANG, XIONGYI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.